Evidence map›Paper›PMID 29706615›Full record

ArticleThe American journal of case reports2018

Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients.

Erica S Tarabadkar, Hannah Thomas, Astrid Blom, Upendra Parvathaneni, Thomas Olencki, Paul Nghiem, Shailender Bhatia

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Merkel cell carcinoma.Skin health and disease · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. FLT3 inhibitors in acute myeloid leukemia.Journal of hematology & oncology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Erica S TarabadkarDepartment of Internal Medicine/Division of Dermatology, University of Washington, Seattle, WA, USA.
Hannah ThomasDepartment of Internal Medicine/Division of Dermatology, University of Washington, Seattle, WA, USA.
Astrid BlomDepartment of Dermatology, Hôpital Ambroise Paré, Boulogne-Billancourt, France.
Upendra ParvathaneniDepartment of Radiation Oncology, University of Washington, Seattle, WA, USA.
Thomas OlenckiDepartment of Internal Medicine/Division of Medical Oncology, The Ohio State University, Columbus, OH, USA.
Paul NghiemDepartment of Internal Medicine/Division of Dermatology, University of Washington, Seattle, WA, USA.
Shailender BhatiaDepartment of Internal Medicine/Division of Medical Oncology, University of Washington, Seattle, WA, USA.
Seattle University · USUniversity of Washington · USHôpital Ambroise-Paré · FRThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin cancer. The estimated 5-year survival of patients with metastatic disease is approximately 14%. Cytotoxic chemotherapy is associated with a modest median progression-free survival (PFS) of only 3 months. In recent studies, immunotherapy with anti-PD-1/anti-PD-L1 antibodies has demonstrated a high response rate in immunocompetent patients (>50% in chemotherapy-naïve patients) and responses are typically durable. However, approximately 50% of immunocompetent patients do not respond to immunotherapy. In addition, immunosuppressed patients have limited therapeutic options. Hence, there is a significant unmet need for effective treatments in these subpopulations. CASE REPORT We describe 5 patients (out of 24 total) with metastatic MCC who were treated with a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), either pazopanib (n=4) or cabozantinib (n=1), with clinical benefit. One patient had a complete response to pazopanib after 3 months of therapy. Four patients had stabilization of disease that lasted from 5 months to 3.5 years. In an immunosuppressed patient with psoriatic arthritis, stabilization of MCC was also associated with improvement in his arthritis that allowed cessation of immunosuppression. Patients did not develop any unusual toxicities from VEGFR-TKIs. CONCLUSIONS Treatment with VEGFR-TKIs demonstrated clinical benefit in this selected small group of patients with metastatic MCC. Prospective investigation of VEGFR-TKIs is warranted in this population, especially in patients with disease refractory to immunotherapy.

Indexed as

AgedAngiogenesis InhibitorsAnilidesAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Merkel CellHumansIndazolesMaleMiddle AgedNeoplasm MetastasisProtein Kinase InhibitorsPyridinesPyrimidinesSkin NeoplasmsSulfonamidesAngiogenesis InhibitorsAnilidescabozantinibIndazolespazopanibProtein Kinase InhibitorsPyridinesPyrimidinesSulfonamides

Identifiers

PMID29706615
PMCPMC5952731
OpenAlexW2801501875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.